The stock price of Emergent Biosolutions Inc (NYSE: EBS) has plunged by -1.16 when compared to previous closing price of 9.47, but the company has seen a -10.52% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-07 that GAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend and NARCAN® Nasal Spray spokesperson, Emmitt Smith, as the city welcomes an anticipated 83,000 fans for the Big Game. For the past two years, Smith has traveled the country sharing his personal connection to the opioid epidemic to help reduce the stigma around accidental opioid poisonings and educate communities on how to save a life with NARCAN® Nasal Spray. Now, as New Orleans gears up to host one of the biggest events of the year, Emergent and Smith will continue these efforts to ensure the city is prepared to act in an opioid emergency, which can happen anytime, anywhere and to anyone.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
The 36-month beta value for EBS is also noteworthy at 1.76. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EBS is 52.75M, and at present, short sellers hold a 13.13% of that float. The average trading volume of EBS on February 13, 2025 was 1.07M shares.
EBS’s Market Performance
The stock of Emergent Biosolutions Inc (EBS) has seen a -10.52% decrease in the past week, with a 0.00% drop in the past month, and a -21.80% fall in the past quarter. The volatility ratio for the week is 5.54%, and the volatility levels for the past 30 days are at 6.05% for EBS. The simple moving average for the past 20 days is -11.10% for EBS’s stock, with a 10.28% simple moving average for the past 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at -3.25% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.01% of loss for the given period.
Volatility was left at 6.05%, however, over the last 30 days, the volatility rate increased by 5.54%, as shares sank -2.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.23% lower at present.
During the last 5 trading sessions, EBS fell by -11.22%, which changed the moving average for the period of 200-days by +383.69% in comparison to the 20-day moving average, which settled at $10.53. In addition, Emergent Biosolutions Inc saw -2.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from DeGolyer Donald W, who sale 25,000 shares at the price of $10.91 back on Nov 12 ’24. After this action, DeGolyer Donald W now owns 111,100 shares of Emergent Biosolutions Inc, valued at $272,750 using the latest closing price.
White Marvin L, the Director of Emergent Biosolutions Inc, sale 14,287 shares at $11.97 during a trade that took place back on Nov 11 ’24, which means that White Marvin L is holding 54,092 shares at $171,015 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.29 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.19. The total capital return value is set at -0.08. Equity return is now at value -34.64, with -12.39 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 213.38. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1.23.
Currently, EBITDA for the company is -505.3 million with net debt to EBITDA at -6.29. When we switch over and look at the enterprise to sales, we see a ratio of 0.31. The receivables turnover for the company is 9.28for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In summary, Emergent Biosolutions Inc (EBS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
